SG Americas Securities LLC grew its stake in Theravance Biopharma Inc (NASDAQ:TBPH) by 52.8% in the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 9,061 shares of the biopharmaceutical company’s stock after acquiring an additional 3,130 shares during the quarter. SG Americas Securities LLC’s holdings in Theravance Biopharma were worth $310,000 at the end of the most recent quarter.

Several other hedge funds also recently made changes to their positions in the company. Parametric Portfolio Associates LLC grew its position in shares of Theravance Biopharma by 1.5% in the 2nd quarter. Parametric Portfolio Associates LLC now owns 14,307 shares of the biopharmaceutical company’s stock valued at $570,000 after purchasing an additional 217 shares during the period. Ameritas Investment Partners Inc. grew its position in shares of Theravance Biopharma by 6.3% in the 2nd quarter. Ameritas Investment Partners Inc. now owns 3,865 shares of the biopharmaceutical company’s stock valued at $153,000 after purchasing an additional 230 shares during the period. Legal & General Group Plc grew its position in shares of Theravance Biopharma by 3.7% in the 2nd quarter. Legal & General Group Plc now owns 16,289 shares of the biopharmaceutical company’s stock valued at $649,000 after purchasing an additional 576 shares during the period. Zacks Investment Management grew its position in shares of Theravance Biopharma by 4.6% in the 2nd quarter. Zacks Investment Management now owns 21,603 shares of the biopharmaceutical company’s stock valued at $861,000 after purchasing an additional 959 shares during the period. Finally, The Manufacturers Life Insurance Company grew its position in shares of Theravance Biopharma by 3.9% in the 2nd quarter. The Manufacturers Life Insurance Company now owns 31,221 shares of the biopharmaceutical company’s stock valued at $1,244,000 after purchasing an additional 1,175 shares during the period. 86.37% of the stock is owned by institutional investors.

Theravance Biopharma Inc (NASDAQ:TBPH) opened at $28.27 on Friday. Theravance Biopharma Inc has a 12-month low of $23.15 and a 12-month high of $43.44. The company has a quick ratio of 7.21, a current ratio of 7.53 and a debt-to-equity ratio of 1.21.

Several equities analysts recently issued reports on the company. Cantor Fitzgerald reiterated a “buy” rating and issued a $55.00 price objective on shares of Theravance Biopharma in a research report on Tuesday, September 26th. Needham & Company LLC reiterated a “buy” rating on shares of Theravance Biopharma in a research report on Tuesday, December 5th. ValuEngine lowered Theravance Biopharma from a “hold” rating to a “sell” rating in a research report on Monday, October 2nd. Robert W. Baird reiterated a “sell” rating and issued a $22.00 price objective on shares of Theravance Biopharma in a research report on Wednesday, November 1st. Finally, Zacks Investment Research upgraded Theravance Biopharma from a “sell” rating to a “hold” rating and set a $37.00 price objective for the company in a research report on Tuesday, October 10th. Three investment analysts have rated the stock with a sell rating, one has issued a hold rating and five have issued a buy rating to the company. The stock presently has a consensus rating of “Hold” and a consensus price target of $41.86.

COPYRIGHT VIOLATION NOTICE: “Theravance Biopharma Inc (TBPH) Stake Increased by SG Americas Securities LLC” was posted by The Cerbat Gem and is the property of of The Cerbat Gem. If you are accessing this piece of content on another site, it was stolen and republished in violation of US and international trademark & copyright legislation. The legal version of this piece of content can be viewed at https://www.thecerbatgem.com/2017/12/17/theravance-biopharma-inc-tbph-stake-increased-by-sg-americas-securities-llc.html.

About Theravance Biopharma

Theravance Biopharma, Inc is a biopharmaceutical company. The Company is engaged in creating medicines for patients suffering from serious illness. The Company operates in the segment of discovery (research), development and commercialization of human therapeutics. The Company’s pipeline of internally discovered product candidates includes medicines to address the unmet needs of patients being treated for serious conditions primarily in the acute care setting.

Want to see what other hedge funds are holding TBPH? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Theravance Biopharma Inc (NASDAQ:TBPH).

Institutional Ownership by Quarter for Theravance Biopharma (NASDAQ:TBPH)

Receive News & Ratings for Theravance Biopharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Theravance Biopharma and related companies with MarketBeat.com's FREE daily email newsletter.